LDL-C calculated by Friedewald, Martin-Hopkins, or NIH equation 2 versus beta-quantification: pooled alirocumab trials.

Ginsberg, Henry N; Rosenson, Robert S; Hovingh, G Kees; Letierce, Alexia; Samuel, Rita; Poulouin, Yann; Cannon, Christopher P

Ginsberg, Henry N; Rosenson, Robert S; Hovingh, G Kees; Letierce, Alexia; Samuel, Rita; Poulouin, Yann; Cannon, Christopher P.

Afiliação

Ginsberg HN; Columbia University, New York, NY, USA. Electronic address: hng1@cumc.columbia.edu.
Rosenson RS; Mount Sinai Icahn School of Medicine, New York, NY, USA.
Hovingh GK; Academic Medical Center, Amsterdam, The Netherlands; Novo Nordisk AS, Copenhagen, Denmark.
Letierce A; Sanofi, Chilly-Mazarin, France.
Samuel R; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Poulouin Y; IT&M Stats, Paris, France.
Cannon CP; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.

J Lipid Res ; 63(1): 100148, 2022 01.

Article em En | MEDLINE | ID: mdl-34774485

Assuntos

LDL-Colesterol

Palavras-chave

Friedewald; LDL; Martin-Hopkins; NIH equation 2; PCSK9; alirocumab; beta-quantification; calculated LDL-C; cholesterol; drug therapy/hypolipidemic drugs

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: LDL-Colesterol Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: LDL-Colesterol Idioma: En Ano de publicação: 2022 Tipo de documento: Article